Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LYRA

Lyra Therapeutics Inc

Apr 18 • 04:00PM ET

5.39

Dollar change -0.02
Percentage change -0.28	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI DWAS VXF IWC DFAC AVSC DFAS DFUS DFAU DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	23.69%	Shs Outstand	57.21M	Perf Week	-0.92%
Market Cap	322.00M	Forward P/E	-	EPS next Y	-1.11	Insider Trans	0.18%	Shs Float	45.59M	Perf Month	-10.76%
Income	-62.68M	PEG	-	EPS next Q	-0.26	Inst Own	61.96%	Short Float	0.49%	Perf Quarter	5.89%
Sales	1.56M	P/S	206.41	EPS this Y	19.81%	Inst Trans	-0.19%	Short Ratio	0.66	Perf Half Y	40.73%
Book/sh	1.56	P/B	3.45	EPS next Y	-10.23%	ROA	-49.63%	Short Interest	0.22M	Perf Year	155.45%
Cash/sh	1.72	P/C	3.13	EPS next 5Y	-1.60%	ROE	-73.67%	52W Range	1.93 - 6.79	Perf YTD	2.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.63%	ROI	-56.54%	52W High	-20.62%	Beta	0.29
Dividend TTM	-	Quick Ratio	5.35	Sales past 5Y	58.51%	Gross Margin	15.25%	52W Low	179.27%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	5.35	EPS Y/Y TTM	38.79%	Oper. Margin	-4205.90%	RSI (14)	46.61	Volatility	6.45% 7.54%
Employees	88	Debt/Eq	0.30	Sales Y/Y TTM	14.31%	Profit Margin	-4023.11%	Recom	1.00	Target Price	12.20
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	40.76%	Payout	-	Rel Volume	1.14	Prev Close	5.41
Sales Surprise	-66.98%	EPS Surprise	39.68%	Sales Q/Q	1227.27%	Earnings	Mar 21 AMC	Avg Volume	339.85K	Price	5.39
SMA20	-4.96%	SMA50	-1.79%	SMA200	27.05%	Trades		Volume	387,833	Change	-0.28%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-23	Resumed	BTIG Research	Buy	$15
Aug-31-23	Initiated	H.C. Wainwright	Buy	$12
May-24-22	Initiated	Cantor Fitzgerald	Overweight	$15
May-26-20	Initiated	William Blair	Outperform
May-26-20	Initiated	Jefferies	Buy	$24
May-26-20	Initiated	BTIG Research	Buy	$28
May-26-20	Initiated	BofA/Merrill	Buy	$21

Mar-28-24 07:08AM	Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock? (Zacks)
Mar-25-24 08:50AM	Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-23-24 05:31AM	Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections (GuruFocus.com)
Mar-22-24 09:55AM	Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High? (Zacks)
Mar-21-24 10:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	Loading…
04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-24 08:50AM	Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going (Zacks)
Mar-01-24 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.17%
Feb-26-24 03:58AM	Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Feb-21-24 08:50AM	Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength (Zacks)
Jan-17-24 08:50AM	What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing' (Zacks)
Nov-07-23 04:01PM	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 07:00AM	Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer (GlobeNewswire)
Sep-13-23 01:22PM	Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up (Zacks)
07:00AM	Loading…
Sep-12-23 07:00AM	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery (GlobeNewswire) +7.48%
Sep-06-23 08:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Aug-08-23 05:50PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:30AM	Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference (GlobeNewswire)
Jun-02-23 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Lyra Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Lyra Therapeutics Announces Closing of $50.0 Million Private Placement (GlobeNewswire) +5.06%
May-26-23 07:57AM	Lyra Therapeutics Announces $50.0 Million Private Placement (GlobeNewswire) +6.58%
May-14-23 08:19AM	Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 08:15AM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:01PM	Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-29-23 08:19AM	Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) biggest owners are retail investors who got richer after stock soared 18% last week (Simply Wall St.)
07:59AM	Loading…
Apr-25-23 07:59AM	Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Mar-29-23 04:06PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-23 01:11PM	Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA) (Simply Wall St.)
Mar-01-23 05:21AM	Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks) -5.04%
Feb-28-23 05:17AM	Lyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 months (Simply Wall St.)
Feb-27-23 07:59AM	Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer (GlobeNewswire)
Feb-07-23 01:23PM	Here's Why We're Watching Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Situation (Simply Wall St.)
Feb-06-23 07:56AM	Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients (GlobeNewswire)
Jan-17-23 06:42PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-20-22 08:52AM	Further weakness as Lyra Therapeutics (NASDAQ:LYRA) drops 15% this week, taking one-year losses to 49% (Simply Wall St.)
Nov-09-22 08:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -15.52%
Nov-08-22 05:45PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 06:11AM	Bullish insiders at Lyra Therapeutics, Inc. (NASDAQ:LYRA) loaded up on US$1.5m of stock earlier this year (Simply Wall St.)
Sep-13-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study (PR Newswire)
Sep-10-22 08:00AM	LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting (PR Newswire)
Sep-08-22 07:00AM	Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients (PR Newswire)
Sep-06-22 07:00AM	Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 (PR Newswire)
Aug-31-22 02:08PM	We're Hopeful That Lyra Therapeutics (NASDAQ:LYRA) Will Use Its Cash Wisely (Simply Wall St.)
Aug-29-22 07:00AM	Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR210 in Two Oral Presentations at ARS Annual Meeting (PR Newswire) +8.52%
Aug-11-22 08:05AM	Are Institutions Heavily Invested In Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) Shares? (Simply Wall St.)
Aug-09-22 08:25AM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-22 09:40AM	Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-22 09:21AM	Increasing losses over year doesn't faze investors as stock rallies 12% this past week (Simply Wall St.)
Jul-05-22 07:00AM	Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire)
07:00AM	Lyra Therapeutics Announces Appointment of Richard Nieman, MD, as Chief Medical Officer (PR Newswire)
Jun-17-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-26-22 07:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-25-22 01:07PM	Peak Sales Potential For This ENT-Focused Stock Is Under-Appreciated, Says Cantor (Benzinga) -7.83%
May-10-22 08:35AM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.62%
07:00AM	Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-05-22 07:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
Apr-29-22 09:07AM	Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022 (PR Newswire) +5.61%
Apr-27-22 06:31AM	7 Stocks to Watch for Major Insider Trading Clues (InvestorPlace) +10.16%
Apr-25-22 07:00AM	Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients (PR Newswire)
Apr-21-22 07:00AM	Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022 (PR Newswire)
Apr-13-22 07:00AM	Lyra Therapeutics Announces Closing of $100.5 Million Private Placement (PR Newswire)
Apr-08-22 07:34AM	Lyra Therapeutics Announces $100.5 Million Private Placement (PR Newswire) +22.22%
Mar-09-22 07:00AM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (PR Newswire) -5.35%
Mar-07-22 07:00AM	Lyra Therapeutics Appoints Jim Tobin to Board of Directors (PR Newswire)
Mar-02-22 04:28AM	Lyra Therapeutics (NASDAQ:LYRA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +6.39%
Feb-28-22 07:00AM	Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients (PR Newswire) -5.44%
Feb-17-22 07:00AM	Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman (PR Newswire) +12.11%
Jan-24-22 12:37PM	Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients (Benzinga)
07:00AM	Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients (PR Newswire)
Nov-11-21 07:00AM	Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences (PR Newswire)
Nov-09-21 04:05PM	Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
Nov-02-21 07:00AM	Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9 (PR Newswire)
Oct-04-21 07:00AM	Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society (PR Newswire)
Sep-29-21 02:58PM	Hedge Funds Are Piling Into Lyra Therapeutics, Inc. (LYRA) (Insider Monkey)
Sep-21-21 07:00AM	Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology (GlobeNewswire)
Sep-20-21 07:00AM	Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data (GlobeNewswire)
Sep-13-21 07:00AM	Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer (GlobeNewswire)
Sep-09-21 04:05PM	Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo Technology Platform in the American Journal of Rhinology & Allergy (GlobeNewswire)
Sep-07-21 07:00AM	Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-03-21 10:24AM	We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-17-21 07:35AM	Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31 (GlobeNewswire)
Aug-09-21 04:05PM	Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments (GlobeNewswire)
Aug-03-21 09:01AM	10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital (Insider Monkey) -5.12%
Jul-26-21 04:05PM	Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9 (GlobeNewswire)
Jul-12-21 07:00AM	Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference (GlobeNewswire)
Jun-30-21 07:00AM	Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis (GlobeNewswire)
Jun-23-21 03:23PM	Should I Avoid Lyra Therapeutics, Inc. (LYRA)? (Insider Monkey)
Jun-09-21 05:48AM	Lyra Therapeutics Stock Is Trading Higher After Positive FDA Meeting Outcome For Rhinosinusitis Program (Benzinga) +17.92%
Jun-08-21 04:30PM	Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis (Business Wire)
Jun-02-21 07:00AM	Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets (Business Wire) +6.95%
Jun-01-21 07:00AM	Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference (Business Wire) +6.27%
May-24-21 07:00AM	Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference (Business Wire)

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waksal Harlan	Executive Chair	Nov 10 '23	Buy	2.96	25,000	74,095	261,966	Nov 13 05:29 PM
PERCEPTIVE ADVISORS LLC	Director	May 31 '23	Buy	2.49	3,610,832	8,999,999	11,469,117	Jun 02 04:11 PM
ANDERSON EDWARD T	Director	May 31 '23	Buy	2.43	1,805,416	4,387,161	2,521,745	Jun 02 04:11 PM
NBVM GP, LLC	10% Owner	May 31 '23	Buy	2.43	1,805,416	4,387,161	2,521,745	Jun 02 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LYRA

Lyra Therapeutics Inc

Upgrade your FINVIZ experience